Active

ARCHER RESEARCH

Switched

BE0538648522

Rechtspersoon Private limited company 1 establishment

Agoralaan A, 3590 Diepenbeek Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg

Active for

13 year

Financials

Financial year 2025

Worth noting

  • Figures corrected afterwards (2024, 2025).

Gross margin

€ 1.6 million

▲ 40% vs 2024

Profit

Growing

€ 566,855

▲ 85% vs 2024

Debts

Low

€ 521,786

▲ 33% vs 2024

ARCHER RESEARCH from Diepenbeek, company number BE0538648522, closed financial year 2025 with a result of € 566,855 after tax. For that financial year ARCHER RESEARCH recorded a gross margin of € 1.6 million and equity of € 1.1 million. Compared with financial year 2024, the result moved from € 306,863 to € 566,855. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 10, 2026.

What happened at ARCHER RESEARCH?

What happened at ARCHER RESEARCH in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

  • Corrected annual accounts filed for financial year 2025. Source: NBB ↗
  • Lana Gybels became a director. NBB
  • FH Impact Management BV stepped down as director. NBB
  • Karen Gabriels became a director. NBB
  • FH Impact Management BV became a director. NBB
  • New establishment in Diepenbeek. KBO
  • Start of the company according to the CBE. KBO

In short

From € 231,835 loss in 2021 to € 566,855 profit in 2025.

Paid € 398,572 in corporate taxes since 2021.

Best year ever: 2025, with € 566,855 profit.

On average € 172,100 of value added per employee in 2025.

A new publication or filing at ARCHER RESEARCH? We notify you, reason included.

Follow ARCHER RESEARCH

Need more data?

History

Every financial year, as far back as the National Bank goes.

Buffer

How long does the company survive without income?

Credit limit

Indicative credit limit, computed from the real figures.

Alerts

New annual account: profit halved. New
Gazette: capital increase of 250k. New

News about who you follow, reason included.

Databakkes Pro · first month free

Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.

Management

Hermes Acquireco 1%
ARCHER RESEARCH

Behind ARCHER RESEARCH are Lana Gybels and Karen Gabriels. The shares are held by Duomed Belgium NV (99%) and Hermes Acquireco (1%).

See the full network in the app

Directors

According to the 2025 annual accounts

Lana Gybels

Director

since 2025

Karen Gabriels

Administrator-manager

since 2024

FH Impact Management BV

Director · represented by Frédéric Hoffmann

Also active at: ORTHOSPINE, DUOMED BELGIUM, Duomed Holding Benelux +2 more

since 2024 · until 2025

Shareholders

Hermes Acquireco

1%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Agoralaan A box bis

3590 Diepenbeek

2.232.335.036

Agoralaan A bis

3590 Diepenbeek

Active since 27 August 2013

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

Details

Company number
0538.648.522
VAT number
BE 0538.648.522
Registered office
Agoralaan A bus bis, 3590 Diepenbeek
Names & denominations
ARCHER RESEARCH
Enterprise type
Rechtspersoon
Legal form
Private limited company
Legal situation
Normale toestand
Start date
27 August 2013
Peppol
Active · Active since 30 Sept 2025
Activities · NACE

Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg

Activiteiten van holdings

Speur- en ontwikkelingswerk op biotechnologisch gebied

Overige gespecialiseerde wetenschappelijke en technische activiteiten

Holdings

Schoonheidsverzorging en andere schoonheidsbehandelingen

Activiteiten van medische beeldvorming en medische laboratoria

Speur- en ontwikkelingswerk op het gebied van de maatschappij- en geesteswetenschappen

+3

Frequently asked questions

What is the enterprise number of ARCHER RESEARCH?
The enterprise number of ARCHER RESEARCH is BE0538648522.
What is the address of ARCHER RESEARCH?
The registered office of ARCHER RESEARCH is located at Agoralaan A box bis, 3590 Diepenbeek.
When was ARCHER RESEARCH founded?
ARCHER RESEARCH was founded on 27 August 2013.
What is the main activity of ARCHER RESEARCH?
The main activity of ARCHER RESEARCH is "Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg" (NACE code 74999).
Does ARCHER RESEARCH have a website?
No website is currently known for ARCHER RESEARCH.
How much profit did ARCHER RESEARCH make in 2025?
ARCHER RESEARCH posted a profit after taxes of € 566,855 in financial year 2025.
What is the revenue of ARCHER RESEARCH?
As a small company, ARCHER RESEARCH is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 1,600,419.
How many employees does ARCHER RESEARCH have?
According to the 2025 annual accounts, ARCHER RESEARCH has 9.3 full-time equivalents (FTE).
Where can I find the annual accounts of ARCHER RESEARCH?
ARCHER RESEARCH files its annual accounts with the Central Balance Sheet Office of the National Bank of Belgium. The key figures for recent financial years are available for free on this page.
Who are the directors of ARCHER RESEARCH?
According to the 2025 annual accounts, the directors of ARCHER RESEARCH are: Lana Gybels, Karen Gabriels, FH Impact Management BV.
Who owns ARCHER RESEARCH?
Behind ARCHER RESEARCH are Lana Gybels and Karen Gabriels. The shares are held by Duomed Belgium NV (99%) and Hermes Acquireco (1%).
Who are the shareholders of ARCHER RESEARCH?
According to the 2025 annual accounts, the shareholders of ARCHER RESEARCH are: Duomed Belgium NV (99%), Hermes Acquireco (1%).